Roth, G. A. et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the global burden of disease Study 2017. Lancet 392, 1736–1788 (2018).
Kinch, M. S., Patridge, E., Plummer, M. & Hoyer, D. An analysis of FDA-approved drugs for infectious disease: antibacterial agents. Drug Discov. Today 19, 1283–1287 (2014).
Munita, J. M. & Arias, C. A. Mechanisms of antibiotic resistance. Microbiol. Spectrum 4, VMBF-0016-2015. (2016).
Sabaté, E. Adherence to Long-Term Therapy: Evidence for Action (WHO, 2003).
Pheage, T. Dying from Lack of Medicines (United Nations, 2016); https://www.un.org/africarenewal/magazine/december-2016-march-2017/dying-lack-medicines
Anselmo, A. C. & Mitragotri, S. Nanoparticles in the clinic. Bioeng. Transl. Med. 1, 10–29 (2016).
Huh, A. J. & Kwon, Y. J. ‘Nanoantibiotics’: a new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era. J. Control. Release 156, 128–145 (2011).
Irvine, D. J., Hanson, M. C., Rakhra, K. & Tokatlian, T. Synthetic nanoparticles for vaccines and immunotherapy. Chem. Rev. 115, 11109–11146 (2015).
Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. mRNA vaccines—a new era in vaccinology. Nat. Rev. Drug Discov. 17, 261–279 (2018).
Kirtane, A. R., Langer, R. & Traverso, G. Past, present, and future drug delivery systems for antiretrovirals. J. Pharm. Sci. 105, 3471–3482 (2016).
Treatment of Tuberculosis: Guidelines 4th edn (WHO, 2010); https://www.who.int/tb/publications/2010/9789241547833/en/
Langer, R. Drug delivery and targeting. Nature 392, 5–10 (1998).
Makadia, H. K. & Siegel, S. J. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers 3, 1377–1397 (2011).
Fielding, R. M., Lewis, R. O. & Moon-McDermott, L. Altered tissue distribution and elimination of amikacin encapsulated in unilamellar, low-clearance liposomes (MiKasome). Pharm. Res. 15, 1775–1781 (1998).
Schiffelers, R., Storm, G. & Bakker-Woudenberg, I. Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies. J. Antimicrob. Chemother. 48, 333–344 (2001).
Trezza, C., Ford, S. L., Spreen, W., Pan, R. & Piscitelli, S. Formulation and pharmacology of long-acting cabotegravir. Curr. Opin. HIV AIDS 10, 239–245 (2015).
Williams, P. E., Crauwels, H. M. & Basstanie, E. D. Formulation and pharmacology of long-acting rilpivirine. Curr. Opin. HIV AIDS 10, 233–238 (2015).
Mcmillan, J. et al. Pharmacokinetics of a long-acting nanoformulated dolutegravir prodrug in rhesus macaques. Antimicrob. Agents Chemother. 62, e01316-17 (2017).
Wistrand-Yuen, E. et al. Evolution of high-level resistance during low-level antibiotic exposure. Nat. Commun. 9, 1599 (2018).
Landovitz, R. J., Kofron, R. & McCauley, M. The promise and pitfalls of long-acting injectable agents for HIV prevention. Curr. Opin. HIV AIDS 11, 122–128 (2016).
das Neves, J., Nunes, R., Machado, A. & Sarmento, B. Polymer-based nanocarriers for vaginal drug delivery. Adv. Drug Deliv. Rev. 92, 53–70 (2015).
Leal, J., Smyth, H. D. C. & Ghosh, D. Physicochemical properties of mucus and their impact on transmucosal drug delivery. Int. J. Pharm. 532, 555–572 (2017).
Cu, Y., Booth, C. J. & Saltzman, W. M. In vivo distribution of surface-modified PLGA nanoparticles following intravaginal delivery. J. Control. Release 156, 258–264 (2011).
Lai, S. K. et al. Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. Proc. Natl Acad. Sci. USA 104, 1482–1487 (2007).
Cunha-Reis, C. et al. Nanoparticles-in-film for the combined vaginal delivery of anti-HIV microbicide drugs. J. Control. Release 243, 43–53 (2016).
Ensign, L. M. et al. Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus. Sci. Transl. Med. 4, 138ra79 (2012).
Palliser, D. et al. An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature 439, 89–94 (2006).
Steinbach, J. M., Weller, C. E., Booth, C. J. & Saltzman, W. M. Polymer nanoparticles encapsulating siRNA for treatment of HSV-2 genital infection. J. Control. Release 162, 102–110 (2012).
Roy, I. & Vij, N. Nanodelivery in airway diseases: challenges and therapeutic applications. Nanomedicine 6, 237–244 (2010).
Han, C. et al. Recent developments in the use of nanoparticles for treatment of biofilms. Nanotechnol. Rev. 6, 383–404 (2017).
Vaughn, J. M. et al. Single dose and multiple dose studies of itraconazole nanoparticles. Eur. J. Pharm. Biopharm. 63, 95–102 (2006).
Alvarez, C. A. et al. Aerosolized nanostructured itraconazole as prophylaxis against invasive pulmonary aspergillosis. J. Infect. 55, 68–74 (2007).
Wong, J. P. et al. Liposome delivery of ciprofloxacin against intracellular Francisella tularensis infection. J. Control. Release 92, 265–273 (2003).
Nafee, N. et al. Antibiotic-free nanotherapeutics: ultra-small, mucus-penetrating solid lipid nanoparticles enhance the pulmonary delivery and anti-virulence efficacy of novel quorum sensing inhibitors. J. Control. Release 192, 131–140 (2014).
Duong, H. T. T. et al. Nanoparticle (star polymer) delivery of nitric oxide effectively negates Pseudomonas aeruginosa biofilm formation. Biomacromolecules 15, 2583–2589 (2014).
Suk, J. S. et al. N-acetylcysteine enhances cystic fibrosis sputum penetration and airway gene transfer by highly compacted DNA nanoparticles. Mol. Ther. 19, 1981–1989 (2011).
Sen, C. K. et al. Human skin wounds: a major and snowballing threat to public health and the economy. Wound Repair Regen. 17, 763–771 (2009).
James, G. A. et al. Biofilms in chronic wounds. Wound Repair Regen. 16, 37–44 (2008).
Martinez, L. R. et al. Antimicrobial and healing efficacy of sustained release nitric oxide nanoparticles against Staphylococcus aureus skin infection. J. Invest. Dermatol. 129, 2463–2469 (2009).
Mohiti-Asli, M., Pourdeyhimi, B. & Loboa, E. G. Skin tissue engineering for the infected wound site: biodegradable PLA nanofibers and a novel approach for silver ion release evaluated in a 3D coculture system of keratinocytes and Staphylococcus aureus. Tissue Eng. Pt C 20, 790–797 (2014).
Sarathy, J. P. et al. Prediction of drug penetration in tuberculosis lesions. ACS Infect. Dis. 2, 552–563 (2016).
Huth, M. E., Ricci, A. J. & Cheng, A. G. Mechanisms of aminoglycoside ototoxicity and targets of hair cell protection. Int. J. Otolaryngol. 2011, 937861 (2011).
Tedijanto, C., Olesen, S. W., Grad, Y. H. & Lipsitch, M. Estimating the proportion of bystander selection for antibiotic resistance among potentially pathogenic bacterial flora. Proc. Natl Acad. Sci. USA 115, E11988–E11995 (2018).
Löbenberg, R., Araujo, L., von Briesen, H., Rodgers, E. & Kreuter, J. Body distribution of azidothymidine bound to hexyl-cyanoacrylate nanoparticles after i.v. injection to rats. J. Control. Release 50, 21–30 (1998).
Kaminishi, H., Tanaka, M., Cho, T., Maeda, H. & Hagihara, Y. Activation of the plasma kallikrein-kinin system by Candida albicans proteinase. Infect. Immun. 58, 2139–2143 (1990).
Molla, A., Yamamoto, T., Akaike, T., Miyoshi, S. & Maeda, H. Activation of hageman factor and prekallikrein and generation of kinin by various microbial proteinases. J. Biol. Chem. 264, 10589–10594 (1989).
Laverman et al. Liposomes for scintigraphic detection of infection and inflammation. Adv. Drug Deliv. Rev. 37, 225–235 (1999).
Laverman, P. et al. Microscopic localization of PEG-liposomes in a rat model of focal infection. J. Control. Release 75, 347–355 (2001).
Siegel, R. A., Kirtane, A. R. & Panyam, J. Assessing the benefits of drug delivery by nanocarriers: a partico/pharmacokinetic framework. IEEE Trans. Biomed. Eng. 64, 2176–2185 (2017).
Gref, R. et al. Biodegradable long-circulating polymeric nanospheres. Science 263, 1600–1603 (1994).
Bakker-Woudenberg, I. A. et al. Liposomes with prolonged blood circulation and selective localization in Klebsiella pneumoniae-infected lung tissue. J. Infect. Dis. 168, 164–171 (1993).
Bakker-Woudenberg, I. A., Lokerse, A. F., ten Kate, M. T. & Storm, G. Enhanced localization of liposomes with prolonged blood circulation time in infected lung tissue. Biochim. Biophys. Acta 1138, 318–326 (1992).
Azad, A. K., Rajaram, M. V. S. & Schlesinger, L. S. Exploitation of the macrophage mannose receptor (CD206) in infectious disease diagnostics and therapeutics. J. Cytol. Mol. Biol. 1, 1000003 (2014).
Chono, S., Tanino, T., Seki, T. & Morimoto, K. Efficient drug targeting to rat alveolar macrophages by pulmonary administration of ciprofloxacin incorporated into mannosylated liposomes for treatment of respiratory intracellular parasitic infections. J. Control. Release 127, 50–58 (2008).
Arias, J. L. et al. Nanobody conjugated PLGA nanoparticles for active targeting of African trypanosomiasis. J. Control. Release 197, 190–198 (2015).
Hussain, S. et al. Antibiotic-loaded nanoparticles targeted to the site of infection enhance antibacterial efficacy. Nat. Biomed. Eng. 2, 95–103 (2018).
Kim, M.-H. et al. Magnetic nanoparticle targeted hyperthermia of cutaneous Staphylococcus aureus infection. Ann. Biomed. Eng. 41, 598–609 (2013).
Luo, Y. et al. Targeted nanoparticles for enhanced X-ray radiation killing of multidrug-resistant bacteria. Nanoscale 5, 687–694 (2013).
Millenbaugh, N., Baskin, J., DeSilva, M., Elliott, W. R. & Glickman, R. Photothermal killing of Staphylococcus aureus using antibody-targeted gold nanoparticles. Int. J. Nanomed. https://doi.org/10.2147/IJN.S76150 (2015).
Xiong, M.-H. et al. Bacteria-responsive multifunctional nanogel for targeted antibiotic delivery. Adv. Mater. 24, 6175–6180 (2012).
Xiong, M.-H. et al. Lipase-sensitive polymeric triple-layered nanogel for ‘on-demand’ drug delivery. J. Am. Chem. Soc. 134, 4355–4362 (2012).
Zhang, C. Y., Gao, J. & Wang, Z. Bioresponsive nanoparticles targeted to infectious microenvironments for sepsis management. Adv. Mater. 30, 1803618 (2018).
Carryn, S. et al. Intracellular pharmacodynamics of antibiotics. Infect. Dis. Clin. North Am. 17, 615–634 (2003).
Tulkens, P. & Trouet, A. The uptake and intracellular accumulation of aminoglycoside antibiotics in lysosomes of cultured rat fibroblasts. Biochem. Pharmacol. 27, 415–424 (1978).
Lutwyche, P. et al. Intracellular delivery and antibacterial activity of gentamicin encapsulated in pH-sensitive liposomes. Antimicrob. Agents Chemother. 42, 2511–2520 (1998).
Clemens, D. L. et al. Targeted Intracellular delivery of antituberculosis drugs to Mycobacterium tuberculosis-infected macrophages via functionalized mesoporous silica nanoparticles. Antimicrob. Agents Chemother. 56, 2535–2545 (2012).
Sémiramoth, N. et al. Self-assembled squalenoylated penicillin bioconjugates: an original approach for the treatment of intracellular infections. ACS Nano 6, 3820–3831 (2012).
Labouta, H. I. et al. Bacteriomimetic invasin-functionalized nanocarriers for intracellular delivery. J. Control. Release 220, 414–424 (2015).
Castoldi, A. et al. Aspherical and spherical InvA497-functionalized nanocarriers for intracellular delivery of anti-infective agents. Pharm. Res. 36, 22 (2019).
Langer, R. & Folkman, J. Polymers for the sustained release of proteins and other macromolecules. Nature 263, 797–800 (1976).
Langer, R. Controlling the movement of molecules. Q. Rev. Biophys. 52, e5 (2019).
Ostro, M. J., Giacomoni, D. & Dray, S. Incorporation of high molecular weight RNA into large artificial lipid vesicles. Biochem. Biophys. Res. Commun. 76, 836–842 (1977).
Martinon, F. et al. Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur. J. Immunol. 23, 1719–1722 (1993).
Kowalski, P. S., Rudra, A., Miao, L. & Anderson, D. G. Delivering the messenger: advances in technologies for therapeutic mRNA Delivery. Mol. Ther. 27, 710–728 (2019).
Chahal, J. S. et al. Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose. Proc. Natl Acad. Sci. USA 113, E4133–E4142 (2016).
Jackson, L. A. et al. An mRNA vccine against SARS-CoV-2—preliminary report. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2022483 (2020).
Feldman, R. A. et al. mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials. Vaccine 37, 3326–3334 (2019).
Tian, J.-H. et al. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice. Nat. Commun. 12, 372 (2021).
Pinto-Alphandary, H. et al. Intracellular visualization of ampicillin-loaded nanoparticles in peritoneal macrophages infected in vitro with Salmonella typhimurium. Pharm. Res. 11, 38–46 (1994).
Toti, U. S. et al. Targeted delivery of antibiotics to intracellular chlamydial infections using PLGA nanoparticles. Biomaterials 32, 6606–6613 (2011).
Teirlinck, E. et al. Laser-induced vapour nanobubbles improve drug diffusion and efficiency in bacterial biofilms. Nat. Commun. 9, 4518 (2018).
Shaaban, M. I., Shaker, M. A. & Mady, F. M. Imipenem/cilastatin encapsulated polymeric nanoparticles for destroying carbapenem-resistant bacterial isolates. J. Nanobiotechnol. 15, 29 (2017).
Nacucchio, M. C., Bellora, M. J., Sordelli, D. O. & D’Aquino, M. Enhanced liposome-mediated activity of piperacillin against staphylococci. Antimicrob. Agents Chemother. 27, 137–139 (1985).
Schiffelers, R. M. et al. In vivo synergistic interaction of liposome-coencapsulated gentamicin and ceftazidime. J. Pharmacol. Exp. Ther. 298, 369–375 (2001).
Miles to Go: Closing Gaps, Breaking Barriers, Righting Injustices (United Nations AIDS, 2018); http://www.unaids.org/en/resources/documents/2018/global-aids-update
Beyrer, C., Wirtz, A. L., O’Hara, G., Léon, N. & Kazatchkine, M. The expanding epidemic of HIV-1 in the Russian Federation. PLoS Med. 14, e1002462 (2017).
HIV in the United States and Dependent Areas (Centers for Disease Control and Prevention, 2019); https://www.cdc.gov/hiv/statistics/overview/ataglance.html
Swindells, S., Flexner, C., Fletcher, C. V. & Jacobson, J. M. The critical need for alternative antiretroviral formulations, and obstacles to their development. J. Infect. Dis. 204, 669–674 (2011).
Olsthoorn, A. V. et al. Barriers to the uptake of postexposure prophylaxis among Nairobi-based female sex workers. AIDS 1, 99–103 (2015).
Wheelock, A. et al. Are Thai MSM willing to take PrEP for HIV prevention? An analysis of attitudes, preferences and acceptance. PLoS ONE 8, e54288 (2013).
Verloes, R. et al. Safety, tolerability and pharmacokinetics of rilpivirine following administration of a long-acting formulation in healthy volunteers. HIV Med. 16, 477–484 (2015).
Ford, S. L. et al. Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744. Antimicrob. Agents Chemother. 57, 5472–5477 (2013).
Margolis, D. A. et al. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial. Lancet Infect. Dis. 15, 1145–1155 (2015).
Sillman, B. et al. Creation of a long-acting nanoformulated dolutegravir. Nat. Commun. 9, 443 (2018).
Freeling, J. P., Koehn, J., Shu, C., Sun, J. & Ho, R. J. Y. Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates. AIDS Res. Hum. Retrov. 31, 107–114 (2015).
Freeling, J. P., Koehn, J., Shu, C., Sun, J. & Ho, R. J. Y. Long-acting three-drug combination anti-HIV nanoparticles enhance drug exposure in primate plasma and cells within lymph nodes and blood. AIDS 28, 2625–2627 (2014).
Kovarova, M. et al. Nanoformulations of rilpivirine for topical pericoital and systemic coitus-independent administration efficiently prevent HIV transmission. PLoS Pathog. 11, e1005075 (2015).
Kirtane, A. R. et al. Development of an oral once-weekly drug delivery system for HIV antiretroviral therapy. Nat. Commun. 9, 2 (2018).
Giardiello, M. et al. Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies. Nat. Commun. 7, 13184 (2016).
World Malaria Report 2018 (WHO, 2018).
Financing Malaria Strategic Plans in Africa in 2018-2020 (RBM Parternship to End Malaria, 2018).
World Malaria Report 2017 (WHO, 2017); http://www.who.int/malaria/publications/world-malaria-report-2017/report/en/
Fidock, D. A. Priming the antimalarial pipeline. Nature 465, 297–298 (2010).
Baird, J. K. Effectiveness of antimalarial drugs. N. Engl. J. Med. 352, 1565–1577 (2005).
Marques, J. et al. Adaptation of targeted nanocarriers to changing requirements in antimalarial drug delivery. Nanomedicine13, 515–525 (2017).
Moles, E. et al. ImmunoPEGliposomes for the targeted delivery of novel lipophilic drugs to red blood cells in a falciparum malaria murine model. Biomaterials 145, 178–191 (2017).
Urban, P. & Fernandez-Busquets, X. Nanomedicine against malaria. Curr. Med. Chem. 21, 605–629 (2014).
Urbán, P., Estelrich, J., Cortés, A. & Fernàndez-Busquets, X. A nanovector with complete discrimination for targeted delivery to Plasmodium falciparum-infected versus non-infected red blood cells in vitro. J. Control. Release 151, 202–211 (2011).
Allen, T. M. & Cullis, P. R. Liposomal drug delivery systems: from concept to clinical applications. Adv. Drug Deliv. Rev. 65, 36–48 (2013).
Joshi, M., Pathak, S., Sharma, S. & Patravale, V. Solid microemulsion preconcentrate (NanOsorb) of artemether for effective treatment of malaria. Int. J. Pharm. 362, 172–178 (2008).
Mandawgade, S. D., Sharma, S., Pathak, S. & Patravale, V. B. Development of SMEDDS using natural lipophile: application to β-artemether delivery. Int. J. Pharm. 362, 179–183 (2008).
Melariri, P. et al. Oral lipid-based nanoformulation of tafenoquine enhanced bioavailability and blood stage antimalarial efficacy and led to a reduction in human red blood cell loss in mice. Int. J. Nanomed. 10, 1493–1503 (2015).
Kumar, S., Singh, R. K., Sharma, R., Murthy, R. S. R. & Bhardwaj, T. R. Design, synthesis and evaluation of antimalarial potential of polyphosphazene linked combination therapy of primaquine and dihydroartemisinin. Eur. J. Pharm. Sci. 66, 123–137 (2015).
Parashar, D., Aditya, N. P. & Murthy, R. S. R. Development of artemether and lumefantrine co-loaded nanostructured lipid carriers: physicochemical characterization and in vivo antimalarial activity. Drug Deliv. 23, 123–129 (2016).
RTS,S Clinical Trials Partnership. A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N. Engl. J. Med. 367, 2284–2295 (2012).
Huang, W.-C. et al. A malaria vaccine adjuvant based on recombinant antigen binding to liposomes. Nat. Nanotechnol. https://doi.org/10.1038/s41565-018-0271-3 (2018).
Global Tuberculosis Report 2018 (WHO, 2018).
Kim, J. Y., Shakow, A., Castro, A. Vande, C. & Farmer, P. Tuberculosis Control: The burden of tuberculosis: Economic burden (2) (World Health Organization, 2003).
O’Neill, J. Tackling Drug-Resistant Infections Globally: Final Report and Recommendations (2016).
Jain, R. et al. in Handbook of Nanomaterials for Industrial Applications Ch. 33 (Elsevier, 2018).
Cohen, J. Approval of novel TB drug celebrated—with restraint. Science 339, 130 (2013).
Singh, H., Jindal, S., Singh, M., Sharma, G. & Kaur, I. P. Nano-formulation of rifampicin with enhanced bioavailability: development, characterization and in-vivo safety. Int. J. Pharm. 485, 138–151 (2015).
Pandey, R., Sharma, S. & Khuller, G. K. Oral solid lipid nanoparticle-based antitubercular chemotherapy. Tuberculosis 85, 415–420 (2005).
Ahmad, Z. & Khuller, G. Alginate-based sustained release drug delivery systems for tuberculosis. Expert Opin. Drug Deliv. 5, 1323–1334 (2008).
Pandey, R. & Khuller, G. K. Nanoparticle-based oral drug delivery system for an injectable antibiotic—streptomycin. Evaluation in a murine tuberculosis model. Chemotherapy 53, 437–441 (2007).
Pandey, R., Zahoor, A., Sharma, S. & Khuller, G. K. Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis. Tuberculosis 83, 373–378 (2003).
Sharma, A., Pandey, R., Sharma, S. & Khuller, G. K. Chemotherapeutic efficacy of poly (DL-lactide-co-glycolide) nanoparticle encapsulated antitubercular drugs at sub-therapeutic dose against experimental tuberculosis. Int. J. Antimicrob. Agents 24, 599–604 (2004).
Costa, A. et al. The formulation of nanomedicines for treating tuberculosis. Adv. Drug Deliv. Rev. 102, 102–115 (2016).
Pandey, R. & Khuller, G. K. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis 85, 227–234 (2005).
Zahoor, A., Sharma, S. & Khuller, G. K. Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. Int. J. Antimicrob. Agents 26, 298–303 (2005).
Chuan, J. et al. Enhanced rifampicin delivery to alveolar macrophages by solid lipid nanoparticles. J. Nanopart. Res. 15, 1634 (2013).
Hawn, T. R. et al. Tuberculosis vaccines and prevention of infection. Microbiol. Mol. Biol. Rev. 78, 650–671 (2014).
Kaufmann, S. H. E., Weiner, J. & von Reyn, C. F. Novel approaches to tuberculosis vaccine development. Int. J. Infect. Dis. 56, 263–267 (2017).
Garcia-Contreras, L. et al. Immunization by a bacterial aerosol. Proc. Natl Acad. Sci. USA 105, 4656–4660 (2008).
Ballester, M. et al. Nanoparticle conjugation and pulmonary delivery enhance the protective efficacy of Ag85B and CpG against tuberculosis. Vaccine 29, 6959–6966 (2011).
Feng, G. et al. Enhanced immune response and protective effects of nano-chitosan-based DNA vaccine encoding T cell epitopes of Esat-6 and FL against Mycobacterium tuberculosis infection. PLoS ONE 8, e61135 (2013).
Liu, Q. et al. Preparation and evaluation of antigen/N-trimethylaminoethylmethacrylate chitosan conjugates for nasal immunization. Vaccine 32, 2582–2590 (2014).
Latent Tuberculosis Infection: Updated and Consolidated Guidelines for Programmtic Management (WHO, 2018).
Van Ginderdeuren, E., Bassett, J., Hanrahan, C., Mutunga, L. & Van Rie, A. Health system barriers to implementation of TB preventive strategies in South African primary care facilities. PLoS ONE 14, e0212035 (2019).
Sundar, S. & Jaya, J. Liposomal amphotericin B and leishmaniasis: dose and response. J. Glob. Infect. Dis. 2, 159–166 (2010).
Mitchell, S. L. & Carlson, E. E. Tiny things with enormous impact: nanotechnology in the fight against infectious disease. ACS Infect. Dis. https://doi.org/10.1021/acsinfecdis.8b00138 (2018).
Desai, N. Challenges in development of nanoparticle-based therapeutics. AAPS J. 14, 282–295 (2012).
Ioannidis, J. P. A., Kim, B. Y. S. & Trounson, A. How to design preclinical studies in nanomedicine and cell therapy to maximize the prospects of clinical translation. Nat. Biomed. Eng. 2, 797–809 (2018).
Satalkar, P., Elger, B. S., Hunziker, P. & Shaw, D. Challenges of clinical translation in nanomedicine: a qualitative study. Nanomedicine 12, 893–900 (2016).
Nanotechnology: A Report of the US Food and Drug Administration Nanotechnology Task Force (USFDA, 2007).
Bhatia, P., Vasaikar, S. & Wali, A. A landscape of nanomedicine innovations in India. Nanotechnol. Rev. 7, 131–148 (2018).
Armstead, A. L. & Li, B. Nanomedicine as an emerging approach against intracellular pathogens. Int. J. Nanomed. 6, 3281–3293 (2011).
Aly, A. S. I., Vaughan, A. M. & Kappe, S. H. I. Malaria parasite development in the mosquito and infection of the mammalian host. Annu. Rev. Microbiol. 63, 195–221 (2009).
Pai, M. et al. Tuberculosis. Nat. Rev. Dis. Prim. 2, 16076 (2016).
Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://www.nature.com/articles/s41565-021-00866-8
